Aptar Pharma’s Preservative-Free Multidose Dispenser Now Available with Allergan’s Eye-Care Medication in the US

Aptar Pharma’s ophthalmic squeeze dispenser is the first and only FDA-approved delivery system for prescription eye-treatment formulations without any preservatives.

Aptar Pharma announced on March 22, 2017 the launch of its patented preservative-free multidose ophthalmic squeeze dispenser, which is now available to patients in the United States with Allergan’s Restasis Multidose (cyclosporine ophthalmic emulsion) 0.05%. This launch makes Aptar Pharma’s ophthalmic squeeze dispenser the first and only FDA-approved delivery system for prescription eye-treatment formulations without any preservatives.

Preservatives in eye-care medications are known to cause irritations and allergic reactions, sometimes resulting in serious side effects. With Aptar Pharma’s ophthalmic squeeze dispenser system, preservatives can be removed from eye-care medications.

Restasis and Restasis Multidose have been approved by FDA for the treatment of chronic dry eyes. These products are not artificial tears, instead, they are prescription medicines that help increase the eye’s natural ability to produce tears. Aptar Pharma is working closely with Allergan to improve patient safety, achieve dosing accuracy, and maintain product integrity.

Aptar Pharma’s ophthalmic squeeze dispenser provides a unique competitive advantage by addressing the global trend toward patient-friendly, cost-effective, and preservative-free multidose dispensers. Patients and consumers in Europe, Latin America, and Asia have benefited from this technology since 2012 with more than 100 commercial references now available on the market.

Source: Aptar Pharma